-
Literature Discussion: Looking at the current situation of HIV drug resistance in African countries from real-world research
Time of Update: 2022-08-30
By the end of March 2021, 838,000 Malawians in the national program had received a dolutegravir-based regimen; viral loads remained greater than 1000 copies/mL after 3 months of intensive adherence support in patients, according to Malawi HIV guidelines may conduct drug resistance testing .
-
The lineup of the 6th IGC 2022 Immune Gene and Cell Therapy Conference has increased
Time of Update: 2022-08-30
com/igc2022Direct access to the latest hot technologies such as in vivo gene editing/LNP/exosomes/AAV/universal cellular immunity/iPSC/MSC stem cell therapy!
com/igc2022Direct access to the latest hot technologies such as in vivo gene editing/LNP/exosomes/AAV/universal cellular immunity/iPSC/MSC stem cell therapy!
-
Analysis of China's innovative drug IND trends
Time of Update: 2022-03-02
Among the new drugs that will apply for IND for the first time in 2021, due to the explosion in the number of double antibodies, the popularity of PDL1, TGF-β, 4-1BB, CD47 and other target combinations has also increased rapidly, and the targets of small molecule drugs are concentrated in KRAS G12C, BTK, SHP2, TOP15 target related drugs totaled 155, accounting for 25% .
-
Molecular Cancer Multi-unit cooperation of Southern Medical University, Zhao Shanchao/Feng Ninghan/Chen Zhesheng discovered potential therapeutic targets for prostate cancer
Time of Update: 2022-01-27
John's University published a joint communication online in Molecular Cancer (IF=27) entitled "Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR- 653-5p", which identified differentially expressed circRNAs by RNA sequencing .
-
Nature Cancer: NTU/Southern Medicine Collaborative Team Reveals New Mechanism of Cancer-Testis lncRNA Promotes Hepatocarcinogenesis and Development
Time of Update: 2022-01-25
m. on January 11, 2022, Beijing time, Nature Cancer, a top international cancer biology journal, published online the latest results of the cooperation between the Drum Tower Hospital Affiliated to Nanjing University School of Medicine and the State Key Laboratory of Reproductive Medicine of Nanjing Medical University - "The cancer- testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription” .
-
Old and unfailing may come true
Time of Update: 2021-12-02
Chinese Academy of Sciences researcher at the Institute of Zoology Zhong ASTRI stem cells and vice Academy of Medical Innovation regeneration president Liu Guanghui: Academy of Sciences Zhong ASTRI ASTRI president Not long ago, some aging codes were deciphered by scientists .
-
Fudan University mBio published a paper: Discovering new key genes for latent HIV infection
Time of Update: 2021-10-11
Zhu Huanzhang team AIDS is an infectious disease caused by human immunodeficiency virus (HIV) infection that seriously endangers people's lives and health .
-
Nearly 200 million dollars
Time of Update: 2021-09-20
Mammoth pioneered the development of these systems to help them overcome many of the obstacles faced by Cas enzymes and to facilitate delivery technologies for genome editing in vivo .
Reference materials:[1] Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics.
-
Bio-Rad launches Reliance SARS-CoV-2/FluA/FluB RT-PCR detection kit in Europe
Time of Update: 2021-08-02
As a global leader in life science research and clinical diagnostic products, BIO-rad Laboratories (NYSE: BIO and BIOb) today announced that after meeting the CE-IVD marking requirements, it will launch Reliance SARS-CoV-2/ for the European market.
-
ASCO 2021: Summary Overview and Outlook 16 | The potential role of ctDNA in predicting colorectal cancer recurrence and overall management
Time of Update: 2021-06-04
ASCO ctDNA test to evaluate colorectal cancerThe purpose of this prospective multi-center study is to determine whether the use of ctDNA testing after multiple operations can identify high-risk relapsed patients, detect relapse earlier than standard radionuclide imaging, and evaluate adjuvant therapy.
-
Phase 3 of LAG-3 antibody reached the primary endpoint
Time of Update: 2021-04-20
According to the information from the Chinese drug clinical trial registration and information disclosure platform, Innovent is conducting an open phase 1 study to evaluate the efficacy of IBI110 single agent and the combination of PD-1 inhibitor Sintilimab in the treatment of subjects with advanced malignant tumors.
-
FDA approves first oral new drug for lupus nephritis
Time of Update: 2021-03-12
On January 22, Aurinia Pharmaceuticals announced FDA approval for Lupkynis (voclosporin, voloxysporin) to be listed as a combination immunosuppressive therapy for the treatment of adult active lupus nephritis (LN).
-
Spark investors cut their holdings as Roche trading was delayed again
Time of Update: 2021-03-01
"In order to give the Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) more time to complete the review, the bid period for Spark shares has been extended from the current deadline of November 25 to December 10," Roche said on Friday.
-
PCR-based detection of a rare linear DNA in cell culture
Time of Update: 2020-12-26
The described method allows for detection of rare linear DNA fragments generated during genomic deletions.
The method was applied to study the short-lived linear DNA generated during programmed genomic deletions in a ciliate.
-
The GUS Reporter System in Flower Development Studies
Time of Update: 2020-11-14
Flower development studies primarily have used the histochemical assay in which inflorescence tissue from transgenic plants containing GUS reporter genes are stained for GUS activity and examined as whole-mounts or subsequently embedded into wax and examined as tissue sections.